Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.44 |
| ▸ | FURIN | P09958 | 2/20 | 0.43 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.43 |
| ▸ | CALCR | P30988 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433320 | 0.93 | FURIN (0.45) | TFPIFURINPRSS1NMT2NMT1 | |
| SCHEMBL31433335 | 0.91 | IL23R (0.48) | IL23RRAMP3CALCR | |
| SCHEMBL30483687 | 0.89 | NPY4R (0.46) | TFPIIL23RFURIN | |
| SCHEMBL30818414 | 0.88 | TFPI (0.50) | TFPIIL23RRAMP3CALCR | |
| SCHEMBL31433357 | 0.88 | TFPI (0.54) | TFPIIL23R | |
| SCHEMBL31433300 | 0.88 | NPY4R (0.45) | TFPI | |
| SCHEMBL31433260 | 0.87 | RAMP3 (0.55) | RAMP3CALCR | |
| SCHEMBL31433268 | 0.87 | RAMP3 (0.55) | RAMP3CALCR | |
| SCHEMBL30569208 | 0.85 | TFPI (0.59) | TFPIIL23R | |
| SCHEMBL29455880 | 0.84 | TFPI (0.53) | TFPIIL23RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | TFPI 2582/4885IL23R 710/4885FURIN 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.